What is the 13F Pro Quality Score for DBVT?

13F Pro ranks DBV Technologies S.A. (DBVT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DBVT's current score at https://13fpro.ai/research/DBVT (free sign-up required for the full ranking).

Where does 13F Pro source DBVT data?

All DBV Technologies S.A. fundamentals and ownership data come directly from SEC EDGAR. DBV Technologies S.A. files with the SEC under CIK 1613780. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DBVT in?

DBV Technologies S.A. (DBVT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DBVT research updated on 13F Pro?

DBVT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

DBV Technologies S.A.(DBVT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1613780 DBVT stock profile & AI dashboard →

13F Pro Quality Score

6.1/100

Rank #2,860 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

11.8/100

Profitability

1.2/100

Balance Sheet

1.3/100

Earnings Quality

30.0/100

Free Cash Flow

0.9/100

Institutional Flow

22.8/100

Revenue Scale

2.3/100

Dilution Risk

3.4/100

DBVT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for DBV Technologies S.A. (DBVT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DBVT at 6.1/100 on a 32-signal composite quality model, placing it at rank #2,860 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.9) and profitability (1.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), DBV Technologies S.A. reports quarterly revenue of $700.0K, net income of $-50.4M, free cash flow of $-53.0M. Top institutional holders of DBVT by reported 13-F value include MPM BioImpact, Vivo Capital,, Artisan Partners Limited Partnership, based on the most recent SEC filings. DBVT trades on the Nasdaq exchange and files with the SEC under CIK 1613780. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DBVT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DBV Technologies S.A. directly from SEC EDGAR.

✦

Fun facts about DBV Technologies S.A.

Quirks, history, and lore behind DBVT — the kind of stuff that makes a stock memorable.

1
The Basics
A French biopharmaceutical company · listed on Nasdaq · focused on developing treatments for allergic diseases · classified as a clinical-stage company.
2
The Numbers
With minimal product revenue and a market cap that has swung wildly on regulatory news, this small-cap biotech lives and dies by FDA decisions — not quarterly sales.
3
The History
Founded in 2002 in France, the company set out to reinvent how the immune system is trained to tolerate allergens — not with shots, but with a skin-based patch.
4
The Secret
Its core technology, called Viaskin, delivers tiny amounts of allergen through the skin to tolerogenic immune cells, aiming to desensitize patients without swallowing or injecting anything.
5
The Lore
Its lead program has been laser-focused on one of the most feared childhood food allergies — peanut allergy — and has faced multiple rounds of FDA back-and-forth that rattled investors.
6
The Giveaway
A transdermal peanut allergy patch for young children, a French biotech with the ticker DBVT, and a regulatory saga that kept allergy-watching parents glued to FDA calendars.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$700.0K

Net Income

Q2 2026

$-50.4M

Free Cash Flow

Q2 2026

$-53.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+35.8% YoY

$5.6MFY 2025

FY20 $11.3MFY21 $5.7MFY24 $4.2MFY25 $5.6M

Net Income

-29.0% YoY

$-146.9MFY 2025

FY20 $-159.6MFY21 $-97.8MFY24 $-113.9MFY25 $-146.9M

Operating Income

-26.1% YoY

$-147.1MFY 2025

FY20 $-158.8MFY21 $-98.6MFY24 $-116.6MFY25 $-147.1M

EPS (Diluted)

+10.3% YoY

$-1.05FY 2025

FY20 —FY21 $-1.78FY24 $-1.17FY25 $-1.05

Total Assets

+256.0% YoY

$233.7MFY 2025

FY20 $272.2MFY21 $146.7MFY24 $65.7MFY25 $233.7M

Total Debt

—FY 2025

FY20 $1.3MFY21 $510.0KFY24 —FY25 —

Op. Cash Flow

-16.0% YoY

$-121.2MFY 2025

FY20 $-165.6MFY21 $-108.2MFY24 $-104.5MFY25 $-121.2M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$5.6M +35.8%	$4.2M -27.3%	$5.7M -49.4%	$11.3M -23.3%	$14.7M +1.2%	$14.5M
Net Income	$-146.9M -29.0%	$-113.9M -16.5%	$-97.8M +38.7%	$-159.6M +7.2%	$-172.0M	—
Operating Income	$-147.1M -26.1%	$-116.6M -18.2%	$-98.6M +37.9%	$-158.8M +7.1%	$-171.0M	—
EPS (Diluted)	$-1.05 +10.3%	$-1.17 +34.3%	$-1.78	—	—	—
Total Assets	$233.7M +256.0%	$65.7M -55.3%	$146.7M -46.1%	$272.2M +0.2%	$271.7M +58.2%	$171.7M
Total Debt	—	—	$510.0K -59.7%	$1.3M -44.1%	$2.3M -20.1%	$2.8M
Operating Cash Flow	$-121.2M -16.0%	$-104.5M +3.5%	$-108.2M +34.6%	$-165.6M -11.6%	$-148.3M	—

Get alerted when DBVT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for DBV Technologies S.A. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DBVT

MPM BioImpact LLC
$108.9M5,213,361 sh
Vivo Capital, LLC
$55.7M2,667,569 sh
Artisan Partners Limited Partnership
$46.4M2,219,386 sh
Siren, L.L.C.
$38.8M1,857,362 sh
BAKER BROS. ADVISORS LP
$30.5M1,461,425 sh
ADAR1 Capital Management, LLC
$21.2M1,012,866 sh
PERCEPTIVE ADVISORS LLC
$20.1M964,391 sh
Patient Square Capital LP
$14.5M693,534 sh
Octagon Capital Advisors LP
$12.0M574,200 sh
Redmile Group, LLC
$10.3M491,340 sh

Fund	Value	Shares
MPM BioImpact LLC	$108.9M	5,213,361
Vivo Capital, LLC	$55.7M	2,667,569
Artisan Partners Limited Partnership	$46.4M	2,219,386
Siren, L.L.C.	$38.8M	1,857,362
BAKER BROS. ADVISORS LP	$30.5M	1,461,425
ADAR1 Capital Management, LLC	$21.2M	1,012,866
PERCEPTIVE ADVISORS LLC	$20.1M	964,391
Patient Square Capital LP	$14.5M	693,534
Octagon Capital Advisors LP	$12.0M	574,200
Redmile Group, LLC	$10.3M	491,340

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DBVT on your watchlist

Track score changes the day DBV Technologies S.A. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DBVT a good stock to buy?

13F Pro's AI-powered analysis of DBV Technologies S.A. (DBVT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DBVT are available on the DBVT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DBVT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DBVT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DBV Technologies S.A.'s investment landscape.